TATVA
Tatva Chintan Pharma Chem Limited
If management delivers what it guided
arithmetic on filed guidance and past valuations · not a price target
TATVA
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹1,788 today
BEAR
₹1,223
-32%
16.1% a year · 58.6x exit
BASE
₹1,874
+5%
27.9% a year · 81.5x exit
BULL
₹5,177
+190%
37.9% a year · 208.8x exit
Where the market has priced it
54x100x today290x
- the guided figure reached earnings through a low-confidence bridge
- FY27 one quarter filed — the pace is shown, not judged: guided +30.0%, filed +42.7% across 1 quarter(s)
- this company's own median multiple sits 260% above its filed-industry peers; the scenario uses its own
How these numbers are produced
| Earnings base | FY26 fiscal year EPS ₹18 (screener) |
|---|---|
| Guided growth | 27.9% a year, said on the call of 21-Jul-2026 · transcript |
| Read across as | operating: unlabelled growth figure, read as revenue — low confidence |
| Delivery calibration | 0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings |
| Exit multiple | 58.57x / 81.52x / 208.84x, this company’s own p20 / median / p80 across 5 filed years |
| Filed-industry peers | median 22.65x across 40 peers — the cross-check, not the input |
| Arithmetic | base EPS × (1 + guided growth × delivery)1 × exit multiple |
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.
What management said
from NSE earnings-call filings · extracted, not interpreted
generic growth 30%
Chintan Shah: We see, yes, so 25%, 30% growth is what we forecasted, and that's what we stick to.
Call 21-Jul-2026 · bridge confidence low · transcript PDF
Pace against its own guidance
FY27
one quarter filed — the pace is shown, not judged
guided 30.0%
filed 42.7%
1 of 4 quarters